Key Takeaways
- • Chinese private equity and venture capital investments in the US plummeted to $5.96 billion in 2025, representing a 78% decline from $26.11 billion in 2021 and a 33% drop from $8.89 billion in 2024, according to S&P Global Market Intelligence data.
- • Deal volume collapsed to 164 transactions in 2025 compared to 438 deals in 2021 and 271 in 2024, reflecting heightened scrutiny under the Foreign Investment Risk Review Modernization Act (CFIUS) targeting technology, infrastructure, and sensitive data investments.
- • US regulatory screening for Chinese investors now presents material risk of deal delay or outright rejection, prompting many Chinese capital allocators to abandon US deployment plans rather than navigate extended approval timelines with uncertain outcomes.
- • Mainland Chinese authorities are simultaneously pressuring domestic funding sources to redirect capital toward domestic priorities, particularly semiconductors, creating dual headwinds against US-focused investment activity.
- • Chinese private equity investors are shifting capital allocation toward Europe and other regions as an alternative to the US market, reflecting a structural redeployment of outbound investment strategy.
Summary
Chinese private equity and venture capital investment in the United States experienced a sharp contraction in 2025, with deal value declining to $5.96 billion for the year through December 23, down significantly from $26.11 billion in 2021 and $8.89 billion in 2024. The volume of transactions fell even more dramatically, with only 164 deals completed in 2025 compared to 438 deals in 2021 and 271 in 2024. This represents a structural deterioration in cross-border capital flows driven by mounting regulatory and geopolitical obstacles, according to S&P Global Market Intelligence data.
The primary constraint on Chinese investment activity stems from enhanced scrutiny under the Foreign Investment Risk Review Modernization Act (CFIUS), which now requires mandatory review of noncontrolling investments in critical technology, critical infrastructure, and sensitive personal data sectors. Julie Fu, greater China M&A and private equity partner at Clifford Chance LLP, attributed the decline to "tighter screening, especially for deals involving technology or data." Nick O'Keefe, partner at Foley & Lardner LLP, noted that the practical impact extends beyond regulatory delay: "For sensitive jurisdictions like China, there is a real risk that the investment could get delayed or blocked. Many companies would rather forgo the investment than accommodate it on a delayed basis, with the risk that it may not get approved."
Compounding regulatory headwinds from the US side, mainland Chinese private equity investors face concurrent pressure from Beijing authorities encouraging domestic capital deployment, particularly in strategic sectors such as semiconductors. This dual pressure—both external regulatory friction and domestic policy incentives—has created a powerful deterrent against US market participation.
In response to these constraints, Chinese outbound capital has begun redirecting toward alternative markets. Fu indicated that "the more stringent deal scrutiny in the US has, to an extent, increased Chinese outbound investment into Europe," suggesting a strategic reallocation rather than a complete withdrawal from cross-border activity. This geographic shift reflects institutional adaptation by Chinese investors seeking jurisdictions with less restrictive regulatory regimes while maintaining international diversification objectives.
The primary constraint on Chinese investment activity stems from enhanced scrutiny under the Foreign Investment Risk Review Modernization Act (CFIUS), which now requires mandatory review of noncontrolling investments in critical technology, critical infrastructure, and sensitive personal data sectors. Julie Fu, greater China M&A and private equity partner at Clifford Chance LLP, attributed the decline to "tighter screening, especially for deals involving technology or data." Nick O'Keefe, partner at Foley & Lardner LLP, noted that the practical impact extends beyond regulatory delay: "For sensitive jurisdictions like China, there is a real risk that the investment could get delayed or blocked. Many companies would rather forgo the investment than accommodate it on a delayed basis, with the risk that it may not get approved."
Compounding regulatory headwinds from the US side, mainland Chinese private equity investors face concurrent pressure from Beijing authorities encouraging domestic capital deployment, particularly in strategic sectors such as semiconductors. This dual pressure—both external regulatory friction and domestic policy incentives—has created a powerful deterrent against US market participation.
In response to these constraints, Chinese outbound capital has begun redirecting toward alternative markets. Fu indicated that "the more stringent deal scrutiny in the US has, to an extent, increased Chinese outbound investment into Europe," suggesting a strategic reallocation rather than a complete withdrawal from cross-border activity. This geographic shift reflects institutional adaptation by Chinese investors seeking jurisdictions with less restrictive regulatory regimes while maintaining international diversification objectives.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.